In the heightened microglial activation response, an exaggerated ROS/c-Abelson murine leukemia viral oncogene homolog (c-Abl)/NLRP3 signaling axis evaluates in LPS-primed rotenone (ROT)-stimulated microglial cells and suggests that targeting c-Abl-regulated NLRP3 inflammasome signaling offers a novel therapeutic strategy for PD treatment (Lawana et al., 2017). Here, ABL1 is linked to Parkinson disease.